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Short Abstract 
There is strong evidence supporting a role of maternal arterial dysfunction in 
pregnancy-specific disorders such as pre-eclampsia and intra-uterine growth 
restriction. As more work is focused towards this field, it is important that methods 
and interpretation of arterial function assessment are utilised appropriately. Here, we 
summarise techniques and devices commonly used in maternal health studies, with 
considerations of technical application within pregnant cohorts. 
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Introduction 
Arterial function is recognised as an important ‘risk marker’ in evaluating 
cardiovascular disease (CVD). There exist several parameters to assess localised 
and global arterial function in both clinical and research settings. These are 
summarised in a consensus report from the European Network for Non-invasive 
Investigation of Large Arteries1, however there lacks specific guidance of use in 
pregnant cohorts. Here, we outline suitable techniques and devices for arterial 
function assessment in pregnancy and interpretation of results. We also summarise, 
in brief, key studies of arterial function in normal and adverse outcome pregnancies. 
The arterial system 
The arterial tree branches from the aorta, terminating in the smallest arterioles, from 
which capillaries arise. Due to the pulsatile nature of cardiac ejection, blood pressure 
(and flow) oscillates throughout the arterial tree. 
Aortic elasticity plays an important role in buffering oscillatory changes in blood 
pressure. Additionally, local adjustments to vascular tone in smooth muscle that 
predominate in smaller arteries and arterioles also help regulate arterial blood flow. 
Common indices of large artery elasticity and vascular tone regulation include 
arterial stiffness, arterial wave reflections and endothelial function, as described 
below. 
 
Arterial stiffness  
Large arteries play an important role in buffering cyclical changes in blood pressure 
(BP), by reducing peak pressure, maintaining diastolic pressure and smoothing 
blood flow. With arterial stiffening, which occurs with age and pathological processes 
such as atherosclerosis or genetic predisposition (e.g. with genes involved in the 
differentiation of vascular smooth muscle cells)2, there is an overall increase in pulse 
pressure, resulting in isolated systolic hypertension.. The repeated cyclical stress of 
a high pulse pressure propagates a vicious cycle of further arterial stiffening through 
fatigue fracture of the elastic elements within the arterial wall. 
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Arterial stiffness can be described by the PWV, which indicates the velocity of blood 
flow in the aorta, which is a large elastin-containing vessel. Augmentation index is 
taken as a proxy of endothelial function in muscular arteries.  
The velocity of the pressure wave is inversely related to vessel elasticity and 
compliance. As arteries stiffen, transmission velocity, commonly expressed as pulse 
wave velocity (PWV) increases. PWV also increases as the pressure wave travels 
from the aorta to the periphery, indicating that vascular compliance is less in the 
distal parts of the arterial tree.  
Aortic PWV (aPWV) is considered the ‘gold standard’ measurement of arterial 
stiffness, as the thoracic and abdominal aorta makes the largest contribution to 
arterial buffering actions, and aPWV is an established independent predictor of 
outcome1. The carotid-femoral pathway is commonly used as a pragmatic 
representative of the aortic system as it covers the region that exhibits the greatest 
age-related stiffening3, and both arteries are superficial and easy to palpate.  
Arterial stiffness defined as aPWV is an independent predictor of CV mortality and 
morbidity in hypertension, type 2 diabetes and end-stage renal failure1. In a meta-
analysis of over 17,000 participants, aPWV reclassified risk and improved model fit 
for future cardiovascular events even after accounting for standard risk factors4. The 
2011 European Society of Hypertension guidelines suggest that in arterial 
hypertension, PWVcf over 10m/s relates to sub-clinical organ damage and 
cardiovascular events5. There are no reported normal limits for PWV in pregnancy, 
although <10m/s is within range for healthy non-pregnant women 6. PWV has been 
reported to increase significantly with maternal weight and age, but not parity or 
smoking status7. 
PWV measurement techniques and devices 
PWV is calculated by measuring the transit time (∆t) taken for a pressure pulse to 
travel between 2 set points; in carotid-femoral PWV (PWVcf), from common carotid 
to the ipsilateral femoral artery. Although direct carotid-femoral measurements are 
preferred, this may not always be feasible. Several non-invasive devices derive the 
distance (D) covered by the pulse wave approximated to surface distance between 
two marked sites. PWV is calculated as PWV= D (meters)/ ∆t (seconds). The foot to 
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foot (with ‘foot’ of pulse wave defined at the end of diastole) measurement of PWVcf 
is shown in Figure 1. 
Measurement of distance is relatively simple with the use of a ruler or measuring 
tape, although the site (for example measuring the carotid wave at or above the 
sternal notch) should always be standardised for all tests within a cohort. In 
pregnancy, metal callipers rather than tape measure is advised due to the distortion 
of linear distance measurements from the shape of the pregnant uterus.  
To measure time delay between pressure wave forms(∆t), there are a variety of 
devices utilising either computerized oscillometry6, applanation tonometry8, Doppler9 
or mechanotransducers10. There is no consensus on which method or device is most 
valid11, 12, and most, due to non-invasive features can be suitably applied in 
pregnancy. Most devices have been validated against invasive testing in non-
pregnant cohorts, but not in pregnancy 13-15. Increment in distending pressure as 
influenced by mean arterial pressure (MAP) increases PWV and, therefore, MAP 
levels need to be taken into account when comparing groups. The effect of heart rate 
is less clear but may be a confounding factor as well16. 
The Complior System® (Colson, France), based on the piezoelectric principle uses 
skin mechanotransducers to detect simultaneous pressure wave forms which can be 
visualised in by the operator. Once waveforms of sufficient quality appear, the ∆t 
between the pressure waveforms at both sites is calculated using a correlation 
algorithm on the initial pulse rise to just after true pulse peak and PWV is calculated  
Pressure waves can also be recorded sequentially at different sites, and ∆t 
calculated from a simultaneous ECG recording. SphygmoCor® (ArtCor, Australia), a 
device with moderate reproducibility17 uses high-fidelity applanation tonometer to 
obtain successive proximal and distal pulses a short time apart. ∆t is then 
determined as the time difference of the ECG R-wave in relation to the distal and 
proximal pulses. As the measurements are a short time apart, changes in heart rate 
variability have minimal effect on ∆t results. 
The Arteriograph® (Tensiomed, Hungary) and Vicorder® (Skidmore Medical Limited, 
United Kingdom) devices uses an oscillometric distension technique to obtain PWV. 
Vicorder® has not been validated against invasive testing for pulse wave analysis, 
however it has been validated against SyphygmoCor® and shows good agreement 
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of aPWV values, though with an inherent bias toward lower Vicorder® aPWV values 
at higher values of SphygmoCor® aPWV18. Arteriograph is based on 
plethysmography and registers pulsatile pressure changes in an artery.  Typically, 
upper arm blood pressure is first measured using a cuff, which is then inflated at 
least 35mmHg over the systolic pressure, and brachial artery pressure fluctuations 
are analysed. The difference in time between the beginning of the first wave and the 
beginning of the second (reflected wave) is related to a measured distance from the 
jugulum to the symphysis, resulting in the PWV. With Vicorder, a pad that inflates 
over several centimetres is placed around patient’s neck, and a cuff is around 
patient’s upper right thigh. Both carotid and femoral cuffs are inflated to 65mmHg 
and the corresponding oscillometric signal from each cuff is obtained in real time. 
Once the operator is satisfied with waveform quality, the test is terminated and an 
algorithm of the two waveforms is analysed to produce ∆t.  
 
Arterial wave reflections 
Another surrogate measure of arterial stiffness is the arterial pressure waveform, 
which is a composite of a forward travelling wave generated by left ventricular 
ejection, and a backward travelling reflected wave arising from sites of impedance 
mismatch such as arterial taper and major arterial bifurcations. The change in 
impedance is thought to generate wave reflections (much like the effect of dropping 
a stone into a small pond, waves hitting the pond edge will be reflected back towards 
the centre) that summate to form a single effective reflected wave that flows back in 
the ascending aorta early in the cardiac cycle.  
As arterial compliance decreases, the reflected wave superimposes on the pulse 
pressure at an earlier time adding to the forward wave and augmenting the systolic 
pressure. This can be quantified through augmentation index (AIx): the ratio of the 
reflected wave to the pulse pressure, and is usually expressed in percentage 
(depicted in Figure 2). While PWV reflects aortic stiffness, AIx is to some extent 
determined by endothelial dysfunction and arterial resistance, and is thought to be a 
more sensitive early marker of arterial stiffness 19. Central AIx has shown 
independent predictive values for all-cause mortality in end stage renal disease 
This article is protected by copyright. All rights reserved.
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patients, and hypertensive patients20, 21. AIx increases linearly with age until 50- 60 
years when it plateaus8, 22.  
 
AIx measurement and devices 
AIx should be analysed at the ascending aorta as that most accurately represents 
the ventricular afterload imposed by central large artery walls. However, it is difficult 
to obtain direct measurements from central arteries, therefore AIx is commonly 
estimated either from the radial or the brachial artery waveforms. Using a validated 
transfer function, an aortic pressure waveform is then calculated. AIx increases with 
mean arterial pressure (MAP) and is inversely related to heart rate and body height, 
so these variables should be accounted for when interpreting results. Commonly, AIx 
is adjusted for a heart rate of 75 beats/min (AIx-75).  In pregnancy, maternal racial 
origin, smoking status, parity, BMI and mean uterine artery PI were not significant 
predictors of AIx-7523. 
 
The most widely used approach is to perform tonometry in the upper limb, usually 
the radial artery, with a high fidelity probe such as the Millar strain gauge transducer 
(SPT-301, Millar Instruments). The pressure waveform analysis is then inputted into 
a transfer function17 (Sphygmocor, AtCor, Australia) to calculate aortic AIx. 
Alternatively, carotid tonometry can be done. For this, a transfer function is not 
necessary as the arterial sites are quite close, and the observed waveforms are 
similar. However carotid tonometry requires more technical expertise and therefore 
there is more room for operator error, especially in obese patients where the carotid 
artery may be more difficult to palpate. 
 
While AIx is a relative measurement and can be calculated without calibration, its 
components: central pulse, heart rate, augmentation and systolic blood pressure are 
absolute values and require calibration1.  
Oscillometric device such as Vicorder® and Arteriograph® (as described above) 
can also be used to analyse pressure waveforms. Brachial artery waveforms are 
obtained using a fluid distension technique via cuff inflation on the upper arm. 
Similar to tonometry, these waveforms are then transformed by a transfer function 
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to give aortic AIx.  No comparative studies between Vicorder® and tonometry have 
been done in pregnancy. In a non-pregnant cohort of COPD patients, AIx 
measurements significantly correlated between Vicorder® and SphygmoCor®, 
however limits of agreement were only -10.42-9.02%, with co-efficient of 
reproducibility of 27.9%24. Vicorder® values were lower but there was satisfactory 
agreement24.  
Arteriograph® obtains AIx from calculating the pressure difference (amplitude 
difference between the start of a first wave P1 and the start of a second reflected 
wave P2) in relation to the pulse pressure (PP). The brachial artery waveform 
readings allow AIx calculation: AIx (%) = [(P2 - P1)/PP] × 100 and thus provides 
the brachial AIx without applying a transfer function. Similarly, there are no 
validation studies of Arteriograph® in pregnancy, however it has been widely used 
in pregnancy research7, 25, 26, and validated against aortic AIx obtained by cardiac 
catheterisation in a non-pregnant cohort13. 
The advantages and disadvantages of commonly used devices for PWV and AIx are 
presented in Table 1. 
 
 
Endothelial function 
The endothelium lines the internal surface of arteries and is sensitive to changes in 
haemodynamic signals and responds by releasing a number of vasodilator 
substances, the most potent of which is nitric oxide, NO, or vasoconstrictors. 
Endothelial injury with resulting dysfunction is associated with atherosclerosis and 
cardiovascular events27.  
Endothelial function is commonly examined by upper arm flow-mediated dilatation 
(FMD) or forearm blood flow (see Table 2 for comparison of advantages of 
techniques). Brachial artery FMD correlates with measures of coronary endothelial 
function28,29. Normal arteries dilate 10%- 15% depending on the position of the cuff 
and equipment used. By definition, if vasodilation does not reach 5%, there is overt 
endothelial dysfunction29. 
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FMD measurement 
FMD measurements as described by Celermajer et al30 has been extensively used 
with good reproducibility and low inter-observer variability31. This technique requires 
an ultrasound system equipped with a high-frequency linear vascular probe, vascular 
software for 2D and colour Doppler imaging, and an internal ECG monitor so that 
each image frame of blood flow can be synchronized to the cardiac cycle. A 
stereotactic probe-holding device will limit measurement error by micro-movements 
of probe by the operator.  
With the subject lying supine, a baseline longitudinal image of the brachial artery with 
clear anterior and posterior intimal interfaces between the lumen and vessel wall is 
first acquired. Then, arterial occlusion is created by a forearm blood pressure cuff 
inflated to suprasystolic pressure for a standardized length of time. Subsequent cuff 
deflation induces a brief high-flow state through the brachial artery (reactive 
hyperaemia) and the resulting increase in shear stress causes endothelium-
dependent vasodilation. The longitudinal image of the artery is recorded continuously 
from 30 seconds before to 2 min after cuff deflation. This continuous imaging period 
should be sufficient to capture peak arterial dilatation, which is reported to occur 
around 57 ± 15 seconds in pregnant women32. At least 10 min of rest is needed after 
reactive hyperaemia before another image is acquired to reflect the reestablished 
baseline conditions.  
If endothelium-independent vasodilation response is to be tested, an exogenous NO 
donor (usually nitroglycerine-NTG spray or sub-lingual tablet) is administered prior to 
the steps above, to determine maximum obtainable vasodilator response 3-4 
minutes after NTG administration. The observed endothelium-independent 
vasodilation reflects vascular smooth muscle function.  
 
FMD is calculated as a percentage change from baseline diameter to the peak 
diameter in response to reactive hyperaemia using the following equation: 
 
FMD (%) = [(peak diameter- baseline diameter)/ baseline diameter] x 100. 
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Forearm blood flow measurement 
Studies have variably used either upper arm or forearm cuff occlusion, and although 
there is no consensus as to which technique provides more precise information, 
forearm blood flow measurement is generally considered the ‘gold standard’ for 
endothelial function testing. Rresistance vessel function in the forearm is assessed 
by strain-gauge venous impedance plethysmography. This works on the underlying 
principle that if venous return from the arm is obstructed and arterial inflow continues 
unimpeded, the forearm swells at a rate proportional to the rate of arterial inflow33. 
The procedure is generally carried out in the following way: a wrist cuff is inflated to 
suprasystolic pressure and 60 seconds allowed before measurements commenced. 
A second cuff is placed around the upper arm and inflated to about 40mmHg (higher 
than venous pressure but lower than diastolic pressure) at intervals of 10 seconds 
with 5 seconds deflation, allowing venous emptying whilst not impeding arterial 
inflow. The arms are positioned above the heart using pads and cushions. A strain 
gauge is placed around the widest part of the arm and the changes in circumference 
(which reflect changes in forearm volume) are measured.  
This test is most useful when comparing dose-response relationships of different 
drugs within a single study, however major drawbacks include reproducibility (due to 
variations in arterial pressure, initial forearm blood flow and forearm size) and more 
invasive nature compared with FMD.  
 
 
Application of arterial function studies in pregnancy 
In normal pregnancy, there is a significant reduction in unadjusted aPWV from pre-
conception to the second trimester (although the reduction is not significant using 
MAP-adjusted PWV). PWV remains low or increases slightly in the third trimester 
and returns to baseline in the post-partum period34, 35. Aortic AIx adjusted for heart 
rate (AIx-75) in normal pregnancy follows a similar pattern to PWV, with the most 
significant changes occurring between pre-pregnancy and the early first trimester36. 
FMD is reported to increase in pregnancy until 32 weeks and decreases significantly 
at 36+ weeks37, 38. 
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Studies of arterial stiffness in complicated pregnancies have been largely focused on 
pre-eclampsia, intra-uterine growth restriction (IUGR), pre-term birth and gestational 
diabetes (GDM) 7, 26, 39, 40; disorders that are associated with higher future CV event 
risk for the mother.  
Arterial function in hypertensive disorders of pregnancy 
All parameters of arterial stiffness in pre-eclamptic women have been found to differ 
significantly from normal pregnancies. In a systematic review of 23 studies 
evaluating the effect of preeclampsia on arterial stiffness, women with preeclampsia 
had elevated arterial stiffness both during and after pregnancy, and to a greater 
extent than in gestational hypertension (GH). More severe presentations of 
preeclampsia was associated with a greater degree arterial stiffness41. It should be 
noted however, that only a few studies in the review adjusted arterial stiffness 
measurements for important variables of maternal heart rate or blood pressure. 
Significantly higher levels of aortic PWV and AIx have also been observed in the 
sub-clinical stage (as early as 11 weeks) of pre-eclampsia23, 40; the magnitude of 
PWV increase in these early phases was similar to that seen in established pre-
eclampsia. Cross-sectional and longitudinal studies that assess arterial stiffness in 
these early sub-clinical stages have shown the potential for arterial stiffness indices 
as a screening test to predict subsequent development of early and late-onset pre-
eclampsia, especially when combined with other maternal variables such as central 
systolic blood pressure7, 40.  
 
Lower FMD has been found in the first and second trimesters among high-risk 
women who subsequently developed preeclampsia, compared to controls42, 43. An 
increase in FMD 4-6 weeks post-partum in women who had preeclampsia, has been 
observed, suggesting a partial reversal of the endothelial dysfunction44. Very few 
studies of endothelial function within pregnancy have included both endothelial 
dependant and endothelial independent measurements, and this may affect findings 
as both processes are intricately related, and have large variations in pregnancy19. 
 
 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Arterial function in fetal growth restriction 
Very few studies have examined PWV in isolated IUGR.  In one which reported 
on small for gestational age babies (which may have included a sub-set of 
IUGR), no differences were found in PWV recorded in the first trimester45. A 
relationship between PWV (third trimester) and birth weight in normal 
pregnancies was found, with an increase of 1 m/sec in PWV associated with a 
decrease in birth weight centiles by 17.6%46. In pregnant women with chronic 
hypertension who subsequently develop both superimposed preeclampsia and fetal 
growth restriction aortic AIx-75 was a determinant of birth weight, and was the only 
significantly elevated haemodynamic parameter in patients who developed fetal 
growth restriction but not superimposed preeclampsia47. Aortic AIx, while normal in 
women with normotensive SGA pregnancies, was elevated in women who later 
presented with pre-eclampsia and SGA fetuses. In postnatal women whose 
pregnancies were affected by IUGR, there was a persistent difference in FMD 
compared to controls, whether hypertensive or not48. This difference was not seen 
when comparing glyceryl trinitrate (GTN) responsiveness between the two groups; 
suggesting they are due to endothelial rather than vascular smooth muscle 
dysfunction.  
Arterial function in diabetes in pregnancy 
Arterial stiffness indices are higher in women with established GDM and in those 
with pre-existing type 2, but not type 1, diabetes mellitus49, 50. Furthermore, women 
who develop GDM have increased arterial stiffness, which are evident from the first 
trimester of pregnancy, suggesting its potential predictive value26. Possible 
mechanisms to explain these associations include alterations in the composition of 
the extracellular matrix and arterial remodeling due to hyperglycemia, and oxidative 
stress, leading to arterial stiffening. Additionally, diabetes is associated with reduced 
nitric oxide production, which may impair endothelial function. 
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Recommendations for assessing arterial function in pregnancy  
• Due to the rapid responses of sympathetic activity and the arterial system to 
internal and external influences, as many variables as possible should be 
standardised across all tests.  
• Before any measurements are performed, adequate acclimatisation to the room 
in which the tests are carried out should be allowed. In general, participants rest 
in the position in which the tests are to be carried out (e.g. supine or sitting) for at 
least 5 minutes before commencement of the tests. For FMD measurements, a 
resting position of about 20 minutes is recommended51.  
• Room temperature should be set at approximately 22-24°C to control for 
orthostatic changes. As several medications that are taken in pregnancy can 
affect arterial function, it is generally recommended that participants refrain from 
taking medication for at least 4 half-lives of the drug prior to testing, where 
possible. Drug and vitamin intake over the last 24 hours should be recorded, and 
co-related to the results. 
• It is recommended that participants abstain from caffeinated drinks at least 4 
hours, and smoking for 12 hours prior to haemodynamic testing. 
• In pregnancy, caval compression from the weight of the gravid uterus can affect 
circulating haemodynamics, therefore it is recommended that tests are carried 
out in the left lateral position. If longitudinal studies are done, this position should 
also be standardized even when the participant is not pregnant or in the first 
trimester.  
• Comparison of results should also be adjusted for any neuro-hormonal 
perturbations associated with pregnancy and fertility e.g. phase of menstrual 
cycle if considering pre-conception studies, or breastfeeding if considering post-
partum assessments. Participants that have undergone hormonal stimulation 
such as follicular priming in IVF may have very different haemodynamics52, and 
this should be taken into account if comparing against women with spontaneous 
conceptions. 
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Recommendations for future research 
• Arterial function testing in pregnancy has largely been focused on identifying 
different haemodynamic signatures in pathological pregnancies. More large scale 
studies are needed to assess and validate the role of arterial function parameters 
in predicting pregnancy complications, as well as assessing its prognostic value, 
whether on its own, or in combination with other biophysical and biochemical 
markers of metabolic dysfunction.  
• Additionally, there lacks an understanding of arterial function changes pre-
conception and in very early pregnancy in relation to pathological pregnancies, 
and therefore longitudinal pre-conception work is needed.  
• There have been a few studies53, 54 assessing the impact of therapy in pregnancy 
on arterial function, but larger scale studies would be helpful in evaluating how 
and to what extent the maternal arterial system responds, and whether treatment 
options can be adjusted to optimise clinical outcomes. 
• To improve the understanding of changes in arterial stiffness, independently of 
confounding factors e.g. maternal heart rate or blood pressure which can change 
significantly in disorders such as pre-eclampsia, studies should report 
appropriately adjuster parameters alongside raw data. 
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 Table 1 Devices for measuring arterial stiffness (Pulse wave velocity [PWV] and 
augmentation index [AIx]). All devices tabulated are non-invasive, and none have 
been validated against invasive techniques in pregnancy. 
 
Technique Advantages Disadvantages 
Mechanotranducer  
Complior® (Alam 
Medical, France) 
• Widely used in the first 
few epidemiological 
studies that 
demonstrated predictive 
value of PWV in 
cardiovascular disorders 
(CVDs). 
• Simultaneous recording 
of central and peripheral 
signal. 
• Portable device 
• Errors associated with 
distance estimation 
signal 
Oscillometric fluid 
distension 
• Arteriograph® 
(Tensiomed, 
Hungary) 
 
• Vicorder® 
(Skidmore Medical, 
UK) 
 
• Affordable 
• Non-invasive 
• Good intra-observer 
variability 
• Can obtain AIx and 
central systolic blood 
pressure(BP) 
 
• Vicorder not yet been 
validated against 
invasive techniques for 
arterial function testing 
Tonometry 
SphymoCor® (AtcCor 
Medical, Australia) 
• Used in many large 
observational studies 
linking arterial function to 
CV events 
 
• Expensive 
• Measured distance is an 
estimation of the true 
distance and largely 
depends on body 
habitus 
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Tonometry 
Omron HEM-9000AI® 
(Omron Healthcare, 
Japan) 
• Similar to SphymoCor 
and can obtain AIx and 
central systolic BP 
• Portable 
• Cannot obtain PWVcf or 
central blood pressures 
Ultrasound 
 
• Can analyse waveforms 
simultaneously or 
separately using ECG 
synchronisation 
• Requires extensive 
training 
• User-dependent 
variability 
Photoplethysmography 
PulseTrace PCA 2 and 
PulseTracePWV® 
(Micro Medical, UK) 
• More suitable for use in 
overweight populations 
• Only give information on 
waveforms at peripheral 
body sites; information 
on central arterial 
waveforms less reliable  
• Inferior quality of 
waveform obtained from 
finger probe 
Cardio-ankle vascular 
index® 
VaSera System 
(Fukuda Denshi, 
Japan) 
• Records distensibility of 
whole aortic-iliac, 
femoral-tibial system 
• Needs further validation 
process in comparison 
to PWVcf 
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Table 2. Techniques for measuring endothelial function 
 
Technique Advantages Disadvantages 
Flow mediated dilatation • Non-invasive 
• Predicts outcome 
• Relatively quick 
assessment 
• Considered a less 
precise method of 
assessment 
• Expensive collateral 
equipment 
Forearm blood flow • Currently gold standard
• Allows assessment of 
basal nitric oxide (NO) 
• Strong co-relation with 
cardiovascular (CV) 
outcomes 
• Invasive 
• Requires specialist 
research setting 
• Time-consuming 
 
 
 
Figure Legends: 
 
Figure 1: Foot to foot measurement of carotid femoral pulse wave velocity 
Figure 2: The arterial waveform complex 
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 1: ‘Foot to foot’ measurement of carotid-femoral pulse wave velocity 
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 2. The arterial waveform complex 
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